Related Experiment Videos
Blood products usage in cardiac surgery
Insights
Patients undergoing cardiac surgery with coagulation defects can often be treated preoperatively. Cardiopulmonary bypass can cause bleeding issues, but lab tests and blood products usually help manage them safely.
Area of Science:
- Cardiovascular Surgery
- Hematology
- Anesthesiology
Background:
- Patients frequently have pre-existing coagulation defects before cardiac surgery.
- Cardiopulmonary bypass (CPB) introduces complex coagulation challenges.
- Assessing isolated coagulation test changes during CPB is difficult due to multiple variables.
Purpose of the Study:
- To review the management of coagulation defects in cardiac surgery.
- To discuss the impact of cardiopulmonary bypass on hemostasis.
- To explore pharmacologic alternatives to blood products for bleeding control.
Main Methods:
- Review of coagulation and fibrinolytic systems during CPB.
- Analysis of laboratory assessment and blood-component usage.
- Evaluation of pharmacologic agents like Desmopressin (DDAVP) and aprotinin.
Main Results:
- CPB induces coagulation abnormalities, but significant bleeding is not always present.
- Laboratory assessment and blood-component therapy can typically correct CPB-induced defects.
- Pharmacologic alternatives show promise but require further investigation for indications and risks.
Conclusions:
- Preoperative correction of coagulation defects is crucial for cardiac surgery.
- While blood products are effective, they carry risks; pharmacologic agents offer potential alternatives.
- Future research should focus on safe and effective bleeding therapies in cardiac surgical patients.
Abstract:
Many patients undergo cardiac surgery with preexisting congenital and acquired coagulation defects. Almost all of these can be recognized and corrected preoperatively. In a complex operation involving the use of cardiopulmonary bypass (CPB), the significance of isolated changes in coagulation tests is difficult to assess. Many variable must be taken into consideration, including the coagulation and fibrinolytic systems, their natural inhibitors, and platelet number and function. CPB induces a variety of abnormalities of coagulation. These abnormalities do not always cause clinically significant bleeding. When they do, laboratory assessment and blood-component usage can usually correct the defect. The use of blood products is associated with allergic, viral, and hemolytic risks. Exciting advances have been made in the use of pharmacologic alternatives to blood products. Both Desmopressin (DDAVP) and aprotinin seem promising in this respect, but more investigation is needed on specific indications for these drugs and on the possible problems with a drug-induced thrombotic tendency. In the future, anesthesiologists and surgeons may look forward to more safe and effective therapy of bleeding in cardiac surgical patients.